Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Recruiting 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 11Sarcoma 2NET 2Endocrine 2Thoracic 1Head & Neck 1Classical hematology 1

Conditions

Sarcoma 70Osteosarcoma 30Sarcoma, Ewing 20Rhabdomyosarcoma 17Ovarian Neoplasms 17Melanoma 17Gastrointestinal Stromal Tumors 16Neuroblastoma 15Bone Neoplasms 13Colorectal Neoplasms 12Wilms Tumor 11Sarcoma, Kaposi 11Rhabdoid Tumor 11Neoplasms 11Lymphoma, Non-Hodgkin 10Liposarcoma 10Hepatoblastoma 10Glioma 10Breast Neoplasms 10Stomach Neoplasms 9Medulloblastoma 9Ependymoma 9Neurofibrosarcoma 8Neuroectodermal Tumors, Primitive, Peripheral 8Neoplasm Metastasis 8Head and Neck Neoplasms 8Glioblastoma 8Carcinoma, Non-Small-Cell Lung 8Carcinoma, Hepatocellular 8Prostatic Neoplasms 7

Interventions

repotrectinib 1Imatinib Mesylate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Digestive System Neoplasms × Sarcoma × 30 days × Clear all
NCT03093116 2026-05-27

TRIDENT-1

Turning Point Therapeutics, Inc.

Phase 1/2 Recruiting
500 enrolled 2 FDA
EndocrineGastrointestinalHead & NeckNETSarcomaThoracic

Adenocarcinoma, Bronchial Neoplasms, Carcinoma, Carcinoma, Bronchogenic, Carcinoma, Non-Small-Cell Lung, Colonic Diseases, Colonic Neoplasms, Digestive System Neoplasms, Endocrine System Diseases, Endocrine Gland Neoplasms, Gastrointestinal Diseases, Gastrointestinal Neoplasms, Head and Neck Neoplasms, Intestinal Diseases, Intestinal Neoplasms, Lung Diseases, Lung Neoplasms, Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Germ Cell and Embryonal, Respiratory Tract Diseases, Respiratory Tract Neoplasms, Sarcoma, Thoracic Neoplasms, Thyroid Diseases, Thyroid Neoplasms, Neuroectodermal Tumors, Carcinoma, Neuroendocrine, Neuroendocrine Tumors

NCT07406633 2026-05-19

KQB198 in Combination With Imatinib in Participants With Advanced/Metastatic GIST in 1st Line Setting

Kumquat Biosciences Inc.

Phase 2 Recruiting
46 enrolled
GastrointestinalSarcoma

Digestive System Neoplasms, Gastrointestinal Stromal Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡